The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study.
 
Erika Joelle Lampert
No Relationships to Disclose
 
Daniel An
No Relationships to Disclose
 
Ann McCoy
No Relationships to Disclose
 
Elise C. Kohn
No Relationships to Disclose
 
Christina M. Annunziata
Research Funding - MaxCyte (Inst); Medivir (Inst); Precision Biologics (Inst)
Patents, Royalties, Other Intellectual Property - MaxCyte (Inst); Precision Biologics (Inst)
 
Kathryn Trewhitt
No Relationships to Disclose
 
Alexandra Dos Santos Zimmer
No Relationships to Disclose
 
Stanley Lipkowitz
No Relationships to Disclose
 
Jung-Min Lee
Research Funding - AstraZeneca (Inst); Lilly (Inst)